Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Ketamine for the Treatment of Rett Syndrome: An Exploratory Trial


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02562820

Organisation Name: The Cleveland Clinic

Overal Status: Terminated

Start Date: November 2015

Last Update: August 30, 2017

Lead Sponsor: The Cleveland Clinic

Brief Summary: Rett Syndrome (RTT) is a complex disorder resulting from mutations in a gene encoding the MeCP2 protein. Currently, there are no methods to fix the abnormal gene, however, animal studies suggest that the symptoms of RTT can be treated.

Ketamine is a sedative or anesthetic, depending on the dose. The drug is approved by the US Food and Drug Administration (FDA) and is commonly used in children and adults. Animal studies and case reports in humans suggest that ketamine may reduce the symptoms of Rett syndrome. The purpose of this study is to determine the safety and efficacy of ketamine for treating breathing and behavioral symptoms of RTT.

Conditions:
  • Rett Syndrome


Total execution time in seconds: 0.42099213600159